Effect of lipopolysaccharide on the xenobiotic-induced expression and activity of hepatic cytochrome P450 in mice

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 4, 2012, Pages 473-480

  Moriya, Nozomu ^a   Kataoka, Hiromi ^b   Fujino, Hideki ^a   Nishikawa, Jun Ichi ^b   Kugawa, Fumihiko ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Cytochrome P450; Hepatic metabolism; Induction; Inflammatory cytokine; Lipopolysaccharide; Transcriptional regulation

Indexed keywords

16ALPHA CYANOPREGNENOLONE; 6BETA HYDROXYTESTOSTERONE; AROMATIC HYDROCARBON RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B10; CYTOCHROME P450 2C29; CYTOCHROME P450 2C55; CYTOCHROME P450 3A11; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; INTERLEUKIN 1BETA; MESSENGER RNA; NIFEDIPINE; PREGNANE X RECEPTOR; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOCHROME P450 1A2 GENE; CYTOCHROME P450 2C29 GENE; CYTOCHROME P450 2C55 GENE; CYTOCHROME P450 3A11 GENE; CYTOKINE RELEASE; DRUG CLEARANCE; ENZYME ACTIVITY; ENZYME REPRESSION; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INDUCTION; HEPATITIS; HYDROXYLATION; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; BENZO(A)PYRENE; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INFLAMMATION; LIPOPOLYSACCHARIDES; LIVER; MALE; MICE; MICE, INBRED BALB C; PREGNENOLONE CARBONITRILE; PYRIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ARYL HYDROCARBON; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; RNA, MESSENGER; XENOBIOTICS;

EID: 84859464923     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.473     Document Type: Article

References (52)

1. Gonzalez FJ. The molecular biology of cytochrome P450s. Pharmacol. Rev., 40, 243-288 (1988).
2. Kraemer MJ, Furukawa CT, Koup JR, Shapiro GG, Pierson WE, Bierman CW. Altered theophylline clearance during an influenza B outbreak. Pediatrics, 69, 476-480 (1982).
3. Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, Richardson TA, Sharma R, Sinal CJ. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab. Dispos., 36, 205-216 (2008).
4. Iber H, Sewer MB, Barclay TB, Mitchell SR, Li T, Morgan ET. Modulation of drug metabolism in infectious and inflammatory diseases. Drug Metab. Rev., 31, 29-41 (1999).
5. Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab. Dispos., 35, 1687-1693 (2007).
6. Yang KH, Lee MG. Effects of endotoxin derived from Escherichia coli lipopolysaccharide on the pharmacokinetics of drugs. Arch. Pharm. Res., 31, 1073-1086 (2008).
7. Morgan ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab. Rev., 29, 1129-1188 (1997).
8. Li-Masters T, Morgan ET. Effects of bacterial lipopolysaccharide on phenobarbital-induced CYP2B expression in mice. Drug Metab. Dispos., 29, 252-257 (2001).
9. Sewer MB, Barclay TB, Morgan ET. Down-regulation of cytochrome P450 mRNAs and proteins in mice lacking a functional NOS2 gene. Mol. Pharmacol., 54, 273-279 (1998).
10. Koj A. Initiation of acute phase response and synthesis of cytokines. Biochim. Biophys. Acta, 1317, 84-94 (1996).
11. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med., 340, 448-454 (1999).
12. Ruminy P, Gangneux C, Claeyssens S, Scotte M, Daveau M, Salier JP. Gene transcription in hepatocytes during the acute phase of a systemic inflammation: from transcription factors to target genes. Inflamm. Res., 50, 383-390 (2001).
13. Li XY, Zhang C, Wang H, Ji YL, Wang SF, Zhao L, Chen X, Xu DX. Tumor necrosis factor alpha partially contributes to lipopoly-saccharide-induced downregulation of CYP3A in fetal liver: its repression by a low dose LPS pretreatment. Toxicol. Lett., 179, 71-77 (2008).
14. Warren GW, Poloyac SM, Gary DS, Mattson MP, Blouin RA. Hepatic cytochrome P-450 expression in tumor necrosis factor-alpha receptor (p55/p75) knockout mice after endotoxin administration. J. Pharmacol. Exp. Ther., 288, 945-950 (1999).
15. Siewert E, Bort R, Kluge R, Heinrich PC, Castell J, Jover R. Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. Hepatology, 32, 49-55 (2000).
16. Morgan ET. Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab. Dispos., 29, 207-212 (2001).
17. Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin. Pharmacol. Ther., 85, 434-438 (2009).
18. Honkakoski P, Negishi M. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem. J., 347, 321-337 (2000).
19. Handschin C, Meyer UA. Induction of drug metabolism: the role of nuclear receptors. Pharmacol. Rev., 55, 649-673 (2003).
20. Birnbaum LS, Baird MB, Massie HR. Pregnenolone-16alpha-carbonitrile- inducible cytochrome P450 in rat liver. Res. Commun. Chem. Pathol. Pharmacol., 15, 553-562 (1976).
21. Goodwin B, Redinbo MR, Kliewer SA. Regulation of cyp3a gene transcription by the pregnane x receptor. Annu. Rev. Pharmacol. Toxicol., 42, 1-23 (2002).
22. Blumberg B, Sabbagh W Jr, Juguilon H, Bolado J Jr, van Meter CM, Ong ES, Evans RM. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev., 12, 3195-3205 (1998).
23. Hernandez JP, Mota LC, Huang W, Moore DD, Baldwin WS. Sexually dimorphic regulation and induction of P450s by the constitutive androstane receptor (CAR). Toxicology, 256, 53-64 (2009).
24. Shimizu Y, Nakatsuru Y, Ichinose M, Takahashi Y, Kume H, Mimura J, Fujii-Kuriyama Y, Ishikawa T. Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc. Natl. Acad. Sci. U.S.A., 97, 779-782 (2000).
25. Squires EJ, Sueyoshi T, Negishi M. Cytoplasmic localization of pregnane X receptor and ligand-dependent nuclear translocation in mouse liver. J. Biol. Chem., 279, 49307-49314 (2004).
26. Konno Y, Kamino H, Moore R, Lih F, Tomer KB, Zeldin DC, Goldstein JA, Negishi M. The nuclear receptors constitutive active/androstane receptor and pregnane x receptor activate the Cyp2c55 gene in mouse liver. Drug Metab. Dispos., 38, 1177-1182 (2010).
27. Shimada T, Sugie A, Shindo M, Nakajima T, Azuma E, Hashimoto M, Inoue K. Tissue-specific induction of cytochromes P450 1A1 and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in engineered C57BL/6J mice of arylhydrocarbon receptor gene. Toxicol. Appl. Pharmacol., 187, 1-10 (2003).
28. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254 (1976).
29. Konno Y, Sekimoto M, Nemoto K, Degawa M. Induction of hepatic cyp2b and cyp3a subfamily enzymes by nicardipine and nifedipine in mice. Xenobiotica, 34, 607-618 (2004).
30. Ashino T, Arima Y, Shioda S, Iwakura Y, Numazawa S, Yoshida T. Effect of interleukin-6 neutralization on CYP3A11 and metallothionein-1/2 expressions in arthritic mouse liver. Eur. J. Pharmacol., 558, 199-207 (2007).
31. Chaluvadi MR, Kinloch RD, Nyagode BA, Richardson TA, Raynor MJ, Sherman M, Antonovic L, Strobel HW, Dillehay DL, Morgan ET. Regulation of hepatic cytochrome P450 expression in mice with intestinal or systemic infections of citrobacter rodentium. Drug Metab. Dispos., 37, 366-374 (2009).
32. Sanada H, Sekimoto M, Kamoshita A, Degawa M. Changes in expression of hepatic cytochrome P450 subfamily enzymes during development of adjuvant-induced arthritis in rats. J. Toxicol. Sci., 36, 181-190 (2011).
33. Assenat E, Gerbal-chaloin S, Maurel P, Vilarem MJ, Pascussi JM. Is nuclear factor kappa-B the missing link between inflammation, cancer and alteration in hepatic drug metabolism in patients with cancer? Eur. J. Cancer, 42, 785-792 (2006).
34. Chaluvadi MR, Nyagode BA, Kinloch RD, Morgan ET. TLR4-dependent and -independent regulation of hepatic cytochrome P450 in mice with chemically induced inflammatory bowel disease. Biochem. Pharmacol., 77, 464-471 (2009).
35. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol., 39, 1-17 (1999).
36. Gharavi N, El-Kadi AO. Down-regulation of aryl hydrocarbon receptor-regulated genes by tumor necrosis factor-α and lipopoly-saccharide in murine hepatoma Hepa 1c1c7 cells. J. Pharm. Sci., 94, 493-506 (2005).
37. Xie W, Tian Y. Xenobiotic receptor meets NF-kappaB, a collision in the small bowel. Cell Metab., 4, 177-178 (2006).
38. Gu X, Ke S, Liu D, Sheng T, Thomas PE, Rabson AB, Gallo MA, Xie W, Tian Y. Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J. Biol. Chem., 281, 17882-17889 (2006).
39. Tian Y, Ke S, Denison MS, Rabson AB, Gallo MA. Ah receptor and NF-kappaB interactions, a potential mechanism for dioxin toxicity. J. Biol. Chem., 274, 510-515 (1999).
40. Ke S, Rabson AB, Germino JF, Gallo MA, Tian Y. Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide. J. Biol. Chem., 276, 39638-39644 (2001).
41. Tian Y. Ah receptor and NF-kappaB interplay on the stage of epigenome. Biochem. Pharmacol., 77, 670-680 (2009).
42. Assenat E, Gerbal-Chaloin S, Larrey D, Saric J, Fabre JM, Maurel P, Vilarem MJ, Pascussi JM. Interleukin 1β inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance. Hepatology, 40, 951-960 (2004).
43. Pascussi JM, Gerbal-Chaloin S, Fabre JM, Maurel P, Vilarem MJ. Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation. Mol. Pharmacol., 58, 1441-1450 (2000).
44. Pascussi JM, Busson-Le Coniat M, Maurel P, Vilarem MJ. Transcriptional analysis of the orphan nuclear receptor constitutive androstane receptor (NR1I3) gene promoter: identification of a distal glucocorticoid response element. Mol. Endocrinol., 17, 42-55 (2003).
45. Ferrari L, Peng N, Halpert JR, Morgan ET. Role of nitric oxide in down-regulation of CYP2B1 protein, but not RNA, in primary cultures of rat hepatocytes. Mol. Pharmacol., 60, 209-216 (2001).
46. Kubota A, Stegeman JJ, Goldstone JV, Nelson DR, Kim EY, Tanabe S, Iwata H. Cytochrome P450 CYP2 genes in the common cormorant: Evolutionary relationships with 130 diapsid CYP2 clan sequences and chemical effects on their expression. Comp. Biochem. Physiol. C Toxicol. Pharmacol., 153, 280-289 (2011).
47. Shimada T, Inoue K, Suzuki Y, Kawai T, Azuma E, Nakajima T, Shindo M, Kurose K, Sugie A, Yamagishi Y, Fujii-Kuriyama Y, Hashimoto M. Arylhydrocarbon receptor-dependent induction of liver and lung cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in genetically engineered C57BL/6J mice. Carcinogenesis, 23, 1199-1207 (2002).
48. Jackson JP, Ferguson SS, Moore R, Negishi M, Goldstein JA. The constitutive active/androstane receptor regulates phenytoin induction of Cyp2c29. Mol. Pharmacol., 65, 1397-1404 (2004).
49. Richardson TA, Morgan ET. Hepatic cytochrome P450 gene regulation during endotoxin-induced inflammation in nuclear receptor knockout mice. J. Pharmacol. Exp. Ther., 314, 703-709 (2005).
50. Wang H, Zhao Y, Bradbury JA, Graves JP, Foley J, Blaisdell JA, Goldstein JA, Zeldin DC. Cloning, expression, and characterization of three new mouse cytochrome p450 enzymes and partial characterization of their fatty acid oxidation activities. Mol. Pharmacol., 65, 1148-1158 (2004).
51. Zhou C, Tabb MM, Nelson EL, Grün F, Verma S, Sadatrafiei A, Lin M, Mallick S, Forman BM, Thummel KE, Blumberg B. Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J. Clin. Invest., 116, 2280-2289 (2006).
52. Naruyama H, Shimada M, Niida H, Zineldeen DH, Hashimoto Y, Kohri K, Nakanishi M. Essential role of Chk1 in S phase progression through regulation of RNR2 expression. Biochem. Biophys. Res. Commun., 374, 79-83 (2008).